Young C W, Yagoda A, Bittar E S, Smith S W, Grabstald H, Whitmore W
Cancer. 1976 Nov;38(5):1887-95. doi: 10.1002/1097-0142(197611)38:5<1887::aid-cncr2820380504>3.0.co;2-#.
Seventy-eight patients with advanced cancer received an adequate therapeutic trial with aniline mustard (NSC 18429). Significant anticancer activity with clinical benefit was demonstrated in five patients with cancer of the prostate and one patient with renal cancer. beta-glucuronidase levels in aspirate and imprint preparations of tumor cells were assessed by a timed cytochemical technique. A partial correlation appeared to exist between very intense glucuronidase staining and tumor regression in prostate and kidney lesions; however, these high levels were observed only rarely. Sequential observations in two patients demonstrated loss of enzymatic activity concomitant with development of clinical relapse.
78例晚期癌症患者接受了苯胺氮芥（NSC 18429）的充分治疗试验。在5例前列腺癌患者和1例肾癌患者中显示出具有临床获益的显著抗癌活性。通过定时细胞化学技术评估肿瘤细胞吸出物和印片制剂中的β-葡萄糖醛酸酶水平。在前列腺和肾脏病变中，非常强烈的葡萄糖醛酸酶染色与肿瘤消退之间似乎存在部分相关性；然而，这些高水平仅很少观察到。对两名患者的连续观察表明，酶活性丧失与临床复发的发生同时出现。
